Evaluation of [Main Substance] in Combination with Other Agents for Patients with Metastatic Clear Cell or Papillary Renal Cell Carcinoma and End-Stage Renal Disease

The primary objective of the study is to evaluate the efficacy and safety of treatment in patients with **Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)** or **papillary renal cell carcinoma (pRCC)** who also have **End-Stage Renal Disease (ESRD)**. This is clinically relevant as it addresses the therapeutic challenges and potential treatment options for a population with complex medical needs, where standard treatment protocols may not be applicable due to compromised renal function.

The clinical trial involves participants diagnosed with **Metastatic Clear Cell Renal Cell Carcinoma** (ccRCC) or papillary renal cell carcinoma (pRCC) and with **End-Stage Renal Disease** (ESRD). The study population includes both male and female subjects, with an age range that encompasses adults and older adults. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population have not been disclosed, and there are no specific lifestyle considerations such as diet or physical activity mentioned. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of an investigational treatment for **Metastatic Clear Cell Renal Cell Carcinoma (ccRCC)** or papillary renal cell carcinoma (pRCC) in patients with **End-Stage Renal Disease (ESRD)**. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias. The trial is set to commence recruitment on June 30, 2023, and is expected to conclude by January 31, 2029, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough review of the participant's medical history, current health status, and any necessary laboratory tests. Following successful screening, participants will be randomly assigned to either the investigational treatment group or the control group. Throughout the trial, participants will attend regular follow-up visits, which will include assessments of treatment efficacy, monitoring of any adverse events, and adjustments to treatment as necessary. These visits are crucial for collecting data on the primary and secondary endpoints of the study.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. During this visit, final assessments will be conducted to evaluate the overall outcomes of the treatment. The expected length of participant involvement will vary depending on individual response to treatment and any unforeseen circumstances. Conditions that may lead to early termination from the study include significant adverse reactions, withdrawal of consent, or any other medical reasons deemed necessary by the investigator. The trial is conducted in accordance with ethical guidelines and regulatory requirements, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a paediatric formulation or if it has orphan drug status. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the study may include non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for any non-experimental treatments is also not available in the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on June 30, 2023, with an estimated completion date of January 31, 2029. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the study duration. The trial's design will ensure that efficacy assessments are conducted systematically to provide reliable and scientifically valid results.